Research team discovers innovative method for Oral Cancer Detection Researchers at Case Western Reserve University School of Dental Medicine have made an outstanding discovery in oral cancer detection. Their new test is non-invasive, cost-effective, and can monitor precancerous lesions. Here's what you need to know about their discovery: The researchers developed a test based on the levels of two proteins in cells collected from suspicious oral lesions. These proteins, known as human beta-defensin 3 (hBD-3) and hBD-2, play crucial roles in early-stage oral cancer detection. By analysing the ratio of hBD-3 to hBD-2 in the lesion site compared to the normal site, they created a scoring system called the beta-defensin index (BDI). A high BDI score suggests the presence of cancer, while a low score indicates benign lesions. The BDI was validated independently at multiple medical centres, confirming its accuracy in distinguishing cancerous from benign lesions. Lead researcher Dr Aaron Weinberg expressed surprise at the discovery, noting that hBD-3, initially believed to aid in wound healing, actually promotes tumour growth. The patented test could reduce the need for biopsies by 95 per cent in primary care clinics, offering a less invasive option for cancer diagnosis. This breakthrough offers hope for more accurate and less invasive oral cancer detection, potentially revolutionising cancer diagnosis and management.